Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma

Cancer Research

Volumn 74, Issue 7, 2014, Pages 1890-1894

  Giannelli, Gianluigi ^a   Villa, Erica ^b   Lahn, Michael ^c  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALUNISERTIB; TRANSFORMING GROWTH FACTOR BETA;

ANTINEOPLASTIC ACTIVITY; BIOACCUMULATION; CANCER SUSCEPTIBILITY; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LIVER NEOPLASMS; PYRAZOLES; QUINOLINES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84897450600     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0243     Document Type: Review

References (29)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A 1981; 78:5339-43.
3. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
4. Heldin CH, Moustakas A. Role of Smads in TGFbeta signaling. Cell Tissue Res 2012;347:21-36.
5. Fransvea E, Mazzocca A, Santamato A, Azzariti A, Antonaci S, Giannelli G. Kinase activation profile associated with TGF-beta-dependent migration of HCC cells: a preclinical study. Cancer Chemother Pharmacol 2011;68:79-86.
6. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 2013;59:583-94.
7. Bissell D. The origin of hepatic myofibroblasts. Mak KM, Leo MA, LieberCS. Alcoholic liver injury in baboons: transformation of lipocytes to transitional cells [Gastroenterology 1984;87:188-200]. J Hepatol 2002;37:298.
8. Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner AM. Intracrine signalling of activin A in hepatocytes upregulates connective tissue growth factor (CTGF/CCN2) expression. Liver Int 2008;28:1207-16.
9. Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatol 2008;47:2059-67.
10. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, C-espedes MV, et al. Dependency of colorectal cancer on a TGFbeta-driven program in stromal cells for metastasis initiation. Cancer Cell 2012;22:571-84.
11. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69: 7385-92.
12. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-61.
13. Behboudi S, Pereira SP. Alpha-fetoprotein specificCD4 and CD8 T cell responses in patients with hepatocellular carcinoma. World J Hepatology 2010;2:256-60.
14. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. TGF-betamiR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 2012;22 291-303.
15. Wu K, Ding J, Chen C, Sun W, Ning BF, Wen W, et al. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 2012;56:2255-67.
16. Dituri F, Mazzocca A, Peidr-o FJ, Papappicco P, Fabregat I, De Santis F, et al. Differential Inhibition of the TGF-beta signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF-beta receptor type II. PLoS ONE 2013;8:e67109.
17. Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008;47: 1557-66.
18. Fransvea E, Angelotti U, Antonaci S, Giannelli G. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 2009;49:839-50.
19. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005;129:1375-83.
20. Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-Talk and tumor progression in hepatocellular carcinoma. Hepatology 2010; 51:523-34.
21. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-Angiogenesis regulation. Hepatology 2009;50:1140-51.
22. Serova M, Tijeras-Raballand A, Dos Santos C, Muller N, Benhadji KA, Paradis V, et al. Effects of TGF-beta signaling inhibition with LY2157299 in hepatocarcinoma models and in ex vivo whole tumor tissue samples from patient specimen [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research;2013 Apr 6-10; Washington, DC. Philadelphia (PA):AACR; 2013. Abstract 2094.
23. Mima K, Hayashi H, Imai K, Kuroki H, Nakagawa S, Okabe H, et al. High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepatobiliary Pancreat Sci 2013;20:429-34.
24. Cui HZ, Dai GH, Shi Y, Chen L. Sorafenib combined with TACE in advanced primary hepatocellular carcinoma. Hepatogastroenterology 2013;60:305-10.
25. Abou-Alfa GK, Schwartz L, Ricci S,Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300.
26. Rodon J, Carducci MA, Sep-ulveda JM, Azaro A, Calvo E, Seoane J, et al. Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor, LY2157299 monohydrate (LY). J Clin Oncol 31, 2013 (suppl; abstr 2016).
27. Giannelli G, Mazzocca A, Fransvea E, Lahn M, Antonaci S. Inhibiting TGF-beta signaling in hepatocellular carcinoma. Biochim Biophys Acta 2011;1815:214-23.
28. Giannelli G, Santoro A, Kelley RK, Merle P, Gane E, Douillard JY, et al. Phase 2 study of the oral transforming growth factor-beta (TGF-beta) receptor I kinase inhibitor LY2157299 [abstract]. In: Proceedings of the 7th ILCA (International Liver Cancer Association) Annual Conference; 2013; Washington, DC. Abstract 0-029.
29. Faivre SJ, Santoro A, Kelley RK, Merle P, Gane E, Douillard JY, et al. A phase 2 study of a novel transforming growth factor-beta (TGF-b1) receptor I kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC). Gastrointestinal Cancers Symposium 2014. San Francisco, California. Abstract LBA173.